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been theorized that metformin could cause the accumu-
lation of lactate under certain metabolic conditions such 
as the substantial tissue hypoperfusion and hypoxia ob-
served in patients with acute heart failure. Although lac-
tic acidosis can be fatal, current evidence indicates that 
any risk associated with metformin itself is minimal.
1   
Indeed, a recent systematic review of metformin use in 
type 2 diabetes with over 70 000 patient-years of follow-
up demonstrated no cases of fatal or nonfatal lactic acid-
osis, although specific effects in those with heart failure 
were not assessed.
2
Despite the fact that this contraindication has pre-
vailed for years, the 2008 Canadian Diabetes Association 
Clinical  Practice  Guidelines  recommended  metformin 
as a first-line therapy in patients with type 2 diabetes 
and heart failure. In addition, despite Health Canada’s 
highly  cautionary  labelling,  more  than  half  (58%)  of   
patients with diabetes and heart failure in Canada are 
currently prescribed metformin.
3 Although the reasons 
for the widespread off-label use of metformin in diabetic 
patients with heart failure is unknown, it is likely attrib-
utable to the general level  of comfort clinicians have with 
the long history of metformin use in Canada, coupled 
with the lack of certainty about the actual potential risk 
of lactic acidosis despite the cautionary labelling.
3
In September 2009, Health Canada approved changes 
to product monographs for metformin that explicitly re-
move the contraindication in patients with heart failure. 
Since then, many of the major manufacturers of met-
formin in Canada (10 out of 18) have updated their prod-
uct monographs to reflect this change. However, these 
product monographs still include a warning against met-
formin’s use in patients with acute, worsening heart fail-
ure, despite the fact that there is no evidence to support 
this concern.
What new evidence has arisen to bring Health Can-
ada’s labelling in line with current guidelines and clin-
ical practice? In the absence of direct head-to-head trials 
evaluating metformin against other oral hypoglycemic 
agents in patients with heart failure, evidence for the 
downgrade in warning comes from observational stud-
ies. Specifically, 2 reports published in 2007  
4,5 were cited 
in  the  revised  product  monographs,  and  6  additional 
observational studies 
6–11 confirmed the same findings:   
metformin is as safe or safer with respect to all adverse 
events than other oral glucose-lowering therapies in pa-
tients with both diabetes and heart failure. Given that 
these  are  observational  rather  than  randomized  con-
trolled studies, it is difficult to say with certainty that 
metformin  is  actually  advantageous  in  heart  failure. 
However, observational studies are the most appropriate 
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eart failure is common in patients with type 2 
diabetes, yet recommended treatment options 
for  glycemic  control  in  this  population  have 
been  limited.  Until  September  2009,  metformin,  the 
first-line treatment for type 2 diabetes in Canada and 
around the world, was long deemed absolutely contra-
indicated for patients with heart failure because of con-
cern about the potential for fatal lactic acidosis. This con-
cern arose not because of lactic acidosis per se with this 
treatment  but  because  of  metformin’s  pharmacologic 
relation to another biguanide, phenformin, which was 
removed from the market in the 1970s because it was   
associated with fatal lactic acidosis. Metformin works 
primarily  in  the  liver  to  decrease  glucose  production 
from lactate, among other substances; it has therefore Open Medicine 2011;5(1):e34
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study design for the evaluation of rare adverse events, 
particularly  in  this  case,  where  there  is  empirical 
evidence  that  randomized  controlled  trials  are  not   
feasible.
3 In fact, we recently terminated a randomized 
placebo-controlled trial of metformin in patients with 
heart failure in view of the already widespread use of 
metformin in this population and the perceived lack of 
support for switching these patients from metformin to 
placebo therapy.
3
The scientific community attempts to limit the use of 
medications when their benefits are unproven or there 
is potential for harm. However, the story of metformin 
and lingering concerns caused by its predecessor, phen-
formin, should remind us that there is another side to 
the patient safety coin: some medications, because of 
inadequate clinical evidence, might initially have been 
considered unsafe on cautionary grounds, with the ef-
fect that important therapeutic options have been inap-
propriately curtailed in some populations. Indications 
for safe treatment need to be revised according to best 
available evidence. The changes in metformin labelling 
occurred very quietly in Canada, and busy clinicians 
might not be aware of them. Perhaps because metform-
in is available in generic form and is already widely used 
in patients with heart failure, there is little metformin-
related pharmaceutical industry promotional activity. 
However, we feel this information is important to bring 
to the attention of Canadian clinicians. We hope that 
these formal regulatory changes, in conjunction with 
support within clinical practice guidelines, will allevi-
ate any lingering concerns clinicians may have about 
continuing or starting metformin in patients with both 
diabetes and heart failure.
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